Literature DB >> 28169304

Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML.

Timothy P Hughes1, David M Ross1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28169304     DOI： 10.1038/nrclinonc.2017.11

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

Authors:  Jun Imagawa; Hideo Tanaka; Masaya Okada; Hirohisa Nakamae; Masayuki Hino; Kazunori Murai; Yoji Ishida; Takashi Kumagai; Seiichi Sato; Kazuteru Ohashi; Hisashi Sakamaki; Hisashi Wakita; Nobuhiko Uoshima; Yasunori Nakagawa; Yosuke Minami; Masahiro Ogasawara; Tomoharu Takeoka; Hiroshi Akasaka; Takahiko Utsumi; Naokuni Uike; Tsutomu Sato; Sachiko Ando; Kensuke Usuki; Satoshi Morita; Junichi Sakamoto; Shinya Kimura
Journal:  Lancet Haematol       Date:  2015-11-10       Impact factor: 18.959

2.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

3.  Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.

Authors:  David M Ross; Paul A Bartley; Jarrad Goyne; Alexander A Morley; John F Seymour; Andrew P Grigg
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

4.  Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Authors:  Philippe Rousselot; Aude Charbonnier; Pascale Cony-Makhoul; Philippe Agape; Franck E Nicolini; Bruno Varet; Martine Gardembas; Gabriel Etienne; Delphine Réa; Lydia Roy; Martine Escoffre-Barbe; Agnès Guerci-Bresler; Michel Tulliez; Stéphane Prost; Marc Spentchian; Jean Michel Cayuela; Josy Reiffers; Jean Claude Chomel; Ali Turhan; Joëlle Guilhot; François Guilhot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

5.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

6.  Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Authors:  Delphine Rea; Franck E Nicolini; Michel Tulliez; François Guilhot; Joelle Guilhot; Agnès Guerci-Bresler; Martine Gardembas; Valérie Coiteux; Gaelle Guillerm; Laurence Legros; Gabriel Etienne; Jean-Michel Pignon; Bruno Villemagne; Martine Escoffre-Barbe; Jean-Christophe Ianotto; Aude Charbonnier; Hyacinthe Johnson-Ansah; Marie-Pierre Noel; Philippe Rousselot; François-Xavier Mahon
Journal:  Blood       Date:  2016-12-08       Impact factor: 22.113

Review 7.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
  7 in total
  3 in total

1.  Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.

Authors:  Simona Bernardi; Michele Malagola; Camilla Zanaglio; Nicola Polverelli; Elif Dereli Eke; Mariella D'Adda; Mirko Farina; Cristina Bucelli; Luigi Scaffidi; Eleonora Toffoletti; Clara Deambrogi; Fabio Stagno; Micaela Bergamaschi; Luca Franceschini; Elisabetta Abruzzese; Maria Domenica Divona; Marco Gobbi; Francesco Di Raimondo; Gianluca Gaidano; Mario Tiribelli; Massimiliano Bonifacio; Chiara Cattaneo; Alessandra Iurlo; Domenico Russo
Journal:  Cancer Med       Date:  2019-04-04       Impact factor: 4.452

Review 2.  Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.

Authors:  Cosimo Cumbo; Luisa Anelli; Giorgina Specchia; Francesco Albano
Journal:  Cancer Manag Res       Date:  2020-05-06       Impact factor: 3.989

3.  Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Authors:  Maria Rosaria Ricciardi; Valentina Salvestrini; Roberto Licchetta; Simone Mirabilii; Mattia Forcato; Gabriele Gugliotta; Simona Salati; Fausto Castagnetti; Gianantonio Rosti; Massimo Breccia; Giuliana Alimena; Rossella Manfredini; Silvio Bicciato; Roberto Massimo Lemoli; Agostino Tafuri
Journal:  Oncotarget       Date:  2018-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.